Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PHILADELPHIA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
-
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
-
Study to be presented by the laboratory of University of Pennsylvania professor Aimee Payne, M.D., Ph.D., Cabaletta co-founder and Scientific Advisory Board co-chair, as a highlighted abstract at the...
-
First IND clearance of a product candidate derived from the CABA™ platform PHILADELPHIA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Company), a clinical-stage biotechnology company...
-
PHILADELPHIA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune...
-
PHILADELPHIA, July 15, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
-
RADNOR, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
-
RADNOR, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
-
Cabaletta Bio Appoints Experienced Financial Executive, Richard Henriques, to its Board of Directors
RADNOR, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases,...
-
Mr. Marda joins Cabaletta with 17 years of financial leadership experience RADNOR, Pa., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and...